| 0 (0%) | 04-24 05:37 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 32.52 | 1-year : | 34.72 |
| Resists | First : | 27.84 | Second : | 29.72 |
| Pivot price | 27.07 |
|||
| Supports | First : | 24.79 | Second : | 20.62 |
| MAs | MA(5) : | 25.97  |
MA(20) : | 27.38 |
| MA(100) : | 25.78 |
MA(250) : | 22.65 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 35.4 |
D(3) : | 21.4 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 33.34 | Low : | 13.72 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PTGX ] has closed above bottom band by 44.9%. Bollinger Bands are 0.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 27.82 - 27.93 | 27.93 - 28.05 |
| Low: | 26.34 - 26.45 | 26.45 - 26.57 |
| Close: | 26.66 - 26.86 | 26.86 - 27.06 |
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Wed, 24 Apr 2024
Long Term Trading Analysis for (PTGX) - News Stock Traders Daily
Tue, 23 Apr 2024
Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting - The Globe and Mail
Sun, 21 Apr 2024
Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Movies UK
Sat, 20 Apr 2024
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Movies Canada
Sat, 13 Apr 2024
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't - Simply Wall St
Fri, 05 Apr 2024
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 58 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 100.4 (%) |
| Shares Short | 3,440 (K) |
| Shares Short P.Month | 2,940 (K) |
| EPS | -1.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.82 |
| Profit Margin | -131.6 % |
| Operating Margin | 38.4 % |
| Return on Assets (ttm) | -19.4 % |
| Return on Equity (ttm) | -28.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.02 |
| EBITDA (p.s.) | -1.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -70 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -19.32 |
| PEG Ratio | 0 |
| Price to Book value | 4.6 |
| Price to Sales | 26.07 |
| Price to Cash Flow | -22.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|